Tuesday, January 26, 2021 Antibody Infusions Prevent Acquisition of Some HIV Strains, NIH Studies Find Model of VRC01, the anti-HIV broadly neutralizing antibody evaluated in the AMP Studies. Credit: NIAID An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Insights gleaned from these trials, known as the Antibody-Mediated Prevention (AMP) Studies, lay the foundation for future development of long-acting antibody-based HIV prevention tools and, ultimately, a vaccine. Results from the trials will be discussed during the 4th HIV Research for Prevention Conference (HIV R4P // Virtual). National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107